标题
CTLA-4 Expression and Its Clinical Significance in Breast Cancer
作者
关键词
-
出版物
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS
Volume 69, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-06-20
DOI
10.1007/s00005-021-00618-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Mechanism‐based treatment of cancer with immune checkpoint inhibitor therapies
- (2020) Yara Abdou et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Tumor-infiltrating regulatory T cells, CD8/Treg ratio, and cancer stem cells are correlated with lymph node metastasis in patients with early breast cancer
- (2020) Luis Alberto Solis-Castillo et al. Breast Cancer
- Prognostic value of immune checkpoint molecules in breast cancer
- (2020) Jun Fang et al. BIOSCIENCE REPORTS
- Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
- (2020) Manuela Terranova-Barberio et al. Nature Communications
- Clinical Implications of Aberrant PD-1 and CTLA4 Expression for Cancer Immunity and Prognosis: A Pan-Cancer Study
- (2020) Jian-Nan Liu et al. Frontiers in Immunology
- Targeting CTLA ‐4 in cancer: Is it the ideal companion for PD ‐1 blockade immunotherapy combinations?
- (2020) Pushpamali De Silva et al. INTERNATIONAL JOURNAL OF CANCER
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Intratumoral, rather than stromal, CD8+ T cells could be a potential negative prognostic marker in invasive breast cancer patients
- (2019) Ivana Catacchio et al. Translational Oncology
- Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
- (2019) Chrétien et al. Cancers
- Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells
- (2019) Saleh et al. Vaccines
- Combination Immunotherapy with Cytotoxic T-Lymphocyte–Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis
- (2019) Ting Sun et al. MOLECULAR CANCER THERAPEUTICS
- New horizons in breast cancer: the promise of immunotherapy
- (2018) L. de la Cruz-Merino et al. Clinical & Translational Oncology
- Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
- (2018) Hope S. Rugo et al. CLINICAL CANCER RESEARCH
- Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer
- (2018) Lina Liu et al. MOLECULAR THERAPY
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Cytotoxic T lymphocyte associated antigen 4 expression predicts poor prognosis in luminal B HER2-negative breast cancer
- (2018) Gaochen Lan et al. Oncology Letters
- A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer
- (2018) Cesar August Santa-Maria et al. Oncotarget
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
- (2018) Alexandra Thomas et al. OncoImmunology
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- (2018) Leisha A. Emens et al. JAMA Oncology
- The clinical promise of immunotherapy in triple-negative breast cancer
- (2018) Praveen Vikas et al. Cancer Management and Research
- Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer
- (2017) Stephen J. Luen et al. PATHOLOGY
- Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition
- (2017) Carlos R. Gil Del Alcazar et al. Cancer Discovery
- CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function
- (2017) Xi Chen et al. Oncotarget
- Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment
- (2017) Azharuddin Sajid Syed Khaja et al. Oncotarget
- Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer
- (2017) Cinzia Solinas et al. Frontiers in Immunology
- Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States
- (2017) Anna Oh et al. Journal of Managed Care & Specialty Pharmacy
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer
- (2016) George Plitas et al. IMMUNITY
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
- (2016) Giampaolo Bianchini et al. Nature Reviews Clinical Oncology
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients
- (2016) Marius Ilie et al. VIRCHOWS ARCHIV
- World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015
- (2016) Shelley McGuire Advances in Nutrition
- Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer
- (2016) Viriya Kaewkangsadan et al. Journal of Immunology Research
- Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes
- (2016) Sasha E. Stanton et al. JAMA Oncology
- Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis
- (2015) Haiming Yu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
- (2015) L. Shamseer et al. BMJ-British Medical Journal
- Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
- (2015) L. Shamseer et al. BMJ-British Medical Journal
- The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
- (2015) Leisha A. Emens et al. Cancer Immunology Research
- Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
- (2014) S. Muenst et al. BREAST CANCER RESEARCH AND TREATMENT
- Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge
- (2014) A. Makkouk et al. CANCER RESEARCH
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
- (2014) Sylvia Adams et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
- (2013) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC
- (2013) Chandan Verma et al. Journal of Translational Medicine
- Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade
- (2012) Leisha A Emens Expert Review of Anticancer Therapy
- New Insights of CTLA-4 into Its Biological Function in Breast Cancer
- (2010) H. Mao et al. CURRENT CANCER DRUG TARGETS
- Breast Cancer Subtypes and the Risk of Local and Regional Relapse
- (2010) K. David Voduc et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started